People

Hovione has announced that Kristine Senft has joined the company as VP, Sales and Marketing and will succeed Dave Hoffman as VP, Sales and Business Development upon his retirement in April 2016. Senft, who was most recently VP, Regenerative Materials at DSM Biomedical, will be based in New Jersey, where Hovione recently announced that it would be doubling the size of … [Read more...] about Kristine Senft appointed VP Sales & Marketing at Hovione

Alexza Pharmaceuticals has promoted Catherine McAuliffe to VP, Operations and Stacy Palermini to VP, Finance, the company said. McAuliffe most recently served as Executive Director, Operations; the position of VP, Operations is newly created. Palermini was previously Executive Director, Finance. Alexza is developing several products using its Staccato inhalation … [Read more...] about Alexza Pharmaceuticals announces two promotions

Insys Therapeutics has announced that it will partner with Senzer Ltd, a subsidiary of Kind Consumer, to develop inhaled dronabinol (THC) and cannabidiol (CBD) products. Insys has licensed Senzer's delivery technology, the same technology in the Voke nicotine inhaler, which was approved in the UK in September 2014. Senzer CEO and Kind Consumer founder Alex Hearn … [Read more...] about Insys to develop inhaled cannabinoids using Voke inhaler technology, hires OINDP specialists

Cirrus Pharmaceuticals announced that it has hired Andrew Hamer as VP R&D. Hamer was most recently Senior Director of R&D Operations at GSK's dermatology subsidiary Stiefel. He also has experience in OINDP development at Cardinal, Sanofi, and Covance. Cirrus, based in Research Triangle Park, NC, was acquired by Kemwell in 2013. It offers inhalation and nasal … [Read more...] about Cirrus Pharmaceuticals hires Andrew Hamer as VP R&D

Intranasal analgesia developer Trigemina Inc. has announced the appointment of Shashidhar "Shashi" Kori as Chief Medical Officer. Trigemina's TI-114 intranasal oxytocin, is in Phase 2 development for the treatment of migraine headaches; the company is also developing an intranasal polypeptide for somatic pain. Kori was most recently Chief Medical officer at … [Read more...] about Trigemina names Shashi Kori as Chief Medical Officer

Moerae Matrix, which is developing inhaled therapies for the treatment of idiopathic pulmonary fibrosis and other lung diseases, has announced the appointment of Bill Bradford as Chief Medical Officer. Bradford was most recently a Senior Fellow at Intermune. Bradford commented, "I am excited to be joining Moerae at this important time in the company's evolution as … [Read more...] about Moerae Matrix hires Bill Bradford as Chief Medical Officer

Current AstraZeneca Vice President Respiratory, Inflammation & Autoimmunity James Ward-Lilley will become CEO of Vectura Group as of October 1 2015. Vectura had previously announced that its current CEO, Chris Blackwell, will be stepping down at the end of June 2015. Ward-Lilley, who has held a variety of roles at AstraZeneca over the past 28 years, commented, "I … [Read more...] about James Ward-Lilley to join Vectura as CEO

Turing Pharmaceuticals, which is developing intranasal oxytocin and ketamine products, has announced that it has hired Eliseo Oreste Salinas as President of Research and Development. Salinas was most recently President and Chief Scientific Officer of Relmada Therapeutics. According to the company, "He arrives as Turing prepares to begin clinical trials for several … [Read more...] about Turing Pharmaceuticals hires Eliseo Salinas as President of R&D